Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Jerusalem Region, Israel Clinical Trials

A listing of Jerusalem Region, Israel clinical trials actively recruiting patients volunteers.

RESULTS

Found (40) clinical trials

Study to Evaluate the Safety Tolerability Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase in Patients With Cystic Fibrosis Previously Treated With Pulmozyme

This is a proof-of-concept, open label study, to evaluate the safety, tolerability, pharmacokinetics and exploratory efficacy of 2.5 mg AIR DNase TM administered once daily for 28 days via inhalation to Cystic Fibrosis subjects who have previously been treated with Pulmozyme. This multicenter study will be conducted in approximately 10 …

Phase

0.0 miles

Learn More »

Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)

This will be an open-label, two-cohort, phase IIa study in subjects with metastatic pancreatic adenocarcinoma. The study will be comprised of 2 cohorts,. Each includes approximately 40 subjects with unresectable metastatic pancreatic adenocarcinoma. Each cohort study consists of two periods: Monotherapy period: One week, with BL-8040 administered daily on days …

Phase

0.0 miles

Learn More »

A Study to Test the Efficacy and Safety of Inhaled TD139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

This study is designed to evaluate the efficacy and safety of TD139, a galectin-3 inhibitor, administered by dry powder inhalation over 52 weeks. Subjects will continue on their existing standard of care (SoC), including pirfenidone or nintedanib. Two doses of TD139, each given once per day, will be compared to …

Phase

0.0 miles

Learn More »

Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)

This study will evaluate the safety, tolerability and pharmacokinetics (PK) of 6 once-monthly doses of oral islatravir (60 mg and 120 mg) compared with placebo in adults at low risk of HIV-1 infection

Phase

0.0 miles

Learn More »

A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy

AML is a heterogeneous disease characterized by uncontrolled clonal expansion of hematopoietic progenitor cells. As the most common form of acute leukemia, AML accounts for the largest number of annual deaths from leukemia. Over 95 percent (%) of AML blasts harvested from newly diagnosed AML participants expressed Cluster of Differentiation …

Phase

0.0 miles

Learn More »

A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

The primary objective is to determine if BIIB093 reduces brain contusion expansion by Hour 96 when compared to placebo. The secondary objectives are to evaluate the effects of BIIB093 on acute neurologic status, functional outcomes, and treatment requirements, to further differentiate the mechanism of action of BIIB093 on contusion expansion …

Phase

0.0 miles

Learn More »

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

Phase

0.0 miles

Learn More »

A Phase 2 Study to Evaluate the Safety Tolerability PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele

This is a Phase 2 open label study to evaluate the safety, tolerability, PK, and PD of multiple dose levels of SC administered ELX-02 in patients with CF with at least one G542X allele. Up to 16 patients will be enrolled in the trial; a minimum of 4 patients will …

Phase

0.0 miles

Learn More »

2-OHOA With RT and TMZ for Adults With Glioblastoma

This is a randomized, double-blind, placebo-controlled, 3 parallel arms (1:1:1 ratio), adjuvant trial to assess the efficacy of two doses of 2-hydroxyoleic acid (2-OHOA) versus placebo in patients with newly diagnosed, IDH wildtype, GBM. In all arms, patients will receive the SoC and will be randomized to receive either placebo, …

Phase

0.0 miles

Learn More »

A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC)

This study is designed to evaluate how the body processes and removes mirikizumab. The study will also evaluate safety and disease response in pediatric participants with UC taking mirikizumab. The study will last about 52 weeks and may include up to 17 visits.

Phase

0.0 miles

Learn More »